Asian Journal of Research in Nursing and Health

Background: Nail lichen planus (NLP) is an inflammatory disorder of the nail unit that can progress to dorsal pterygium, anonychia, and permanent dystrophy. Expert opinion describes it as a condition requiring prompt treatment, but the clinical signs that precede irreversible damage, and the existence of a time-limited therapeutic window, have not been critically appraised.
Objective: To determine which early clinical findings of NLP have been associated with subsequent irreversible nail damage, and what evidence supports early treatment as a means of preventing permanent nail destruction and improving long-term outcomes.
Evidence Synthesis: PubMed and supplementary web, publisher, and registry sources were searched from inception to 31 August 2026. Clinical cohorts, case series, treatment reports, consensus statements, and prior reviews were classified by evidence type, and each candidate sign was assigned to one of five prognostic categories: longitudinal predictor, marker of active disease, marker of established damage, cross-sectional association, or proposed predictor.
Key Findings: No clinical sign met criteria for a longitudinally validated predictor of irreversible damage. Longitudinal ridging, fissuring, thinning, trachyonychia, and red lunula behave as markers of active matrix disease. In a photographic series of 102 patients, distal splitting >50%, onychoatrophy, and loss of the proximal nail fold limits were cross-sectionally associated with pterygium, and severe thinning and nail bed or plate retraction with anonychia. Evidence that longer disease duration favours pterygium is small and conflicting. No study compared outcomes by time to treatment, and no therapeutic window has been defined. Long-term data are limited: in 27 patients followed for more than 5 years, 18 were cured, 9 did not respond to corticosteroids, and 11 relapsed. Nail-level data suggest that established irreversible changes remain stable rather than regress during intramatricial treatment, and that toenails respond less well than fingernails.
Conclusion: Prompt treatment of NLP rests on biological plausibility and expert consensus rather than on demonstrated prevention of scarring. Recognising advanced matrix signs as a possible high-risk stage is reasonable but unvalidated. Prospective, nail-level cohorts with standardised severity and damage scores and recorded time to treatment are needed to test whether a therapeutic window exists.